Search
- Page Path
- HOME > Search
Original Article
- Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis
- Seyed Davar Siadat, Farzam Vaziri, Mamak Eftekhary, Maryam Karbasian, Arfa Moshiri, Mohammad R. Aghasadeghi, Mehdi S. Ardestani, Meghdad Abdollahpour Alitappeh, Amin Arsang, Abolfazl Fateh, Shahin Najar Peerayeh, Ahmad R. Bahrmand
- Osong Public Health Res Perspect. 2015;6(1):9-13. Published online February 28, 2015
- DOI: https://doi.org/10.1016/j.phrp.2014.10.012
- 4,179 View
- 25 Download
- 6 Crossref
-
Abstract
PDF - Objectives
Development of an efficacious vaccine against brucellosis has been a challenge for scientists for many years. At present, there is no licensed vaccine against human brucellosis. To overcome this problem, currently, antigenic determinants of Brucella cell wall such as Lipopolysaccharide (LPS) are considered as potential candidates to develop subunit vaccines.
Methods
In this study, Brucella abortus LPS was used for conjugation to Neisseria meningitidis serogroup B outer membrane vesicle (OMV) as carrier protein using carbodiimide and adipic acid–mediated coupling and linking, respectively. Groups of eight BALB/c mice were injected subcutaneously with 10 μg LPS alone, combined LPS + OMV and conjugated LPS–OMV on 0 days, 14 days, 28 days and 42 days. Anti-LPS IgG was measured in serum.
Results
The yield of LPS to OMV in LPS–OMV conjugate was 46.55%, on the basis of carbohydrate content. The ratio for LPS to OMV was 4.07. The LPS–OMV conjugate was the most immunogenic compound that stimulated following the first injection with increased IgG titer of ∼5-fold and ∼1.3-fold higher than that produced against LPS and LPS in noncovalent complex to OMV (LPS + OMV), respectively. The highest anti-LPS IgG titer was detected 2 weeks after the third injection (Day 42) of LPS–OMV conjugate. The conjugated compound elicited higher titers of IgG than LPS + OMV, that showed a 100–120-fold rise of anti-LPS IgG in mice.
Conclusion
These results indicate that our conjugated LPS–OMV can be used as a brucellosis vaccine, but further investigation is required. -
Citations
Citations to this article as recorded by
- Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy
Qiong Long, Peng Zheng, Xiao Zheng, Weiran Li, Liangqun Hua, Zhongqian Yang, Weiwei Huang, Yanbing Ma
Advanced Drug Delivery Reviews.2022; 186: 114321. CrossRef - Isolation of Extracellular Vesicles of Akkermansia muciniphila as a Potential Therapeutic Platform
Pegah Noori, Fattah Sotoodehnejadnematalali, Pooneh Rahimi, Seyed davar Siadat
Vaccine Research.2022; 9(2): 27. CrossRef - Novel Simple Conjugation Chemistries for Decoration of GMMA with Heterologous Antigens
Roberta Di Benedetto, Renzo Alfini, Martina Carducci, Maria Aruta, Luisa Lanzilao, Alessandra Acquaviva, Elena Palmieri, Carlo Giannelli, Francesca Necchi, Allan Saul, Francesca Micoli
International Journal of Molecular Sciences.2021; 22(19): 10180. CrossRef - Outer membrane vesicle vaccines
Francesca Micoli, Calman A. MacLennan
Seminars in Immunology.2020; 50: 101433. CrossRef -
Designing an immunosensor for detection of
Brucella abortus
based on coloured silica nanoparticles
Arash Shams, Bahareh Rahimian Zarif, Mojtaba Salouti, Reza Shapouri, Sako Mirzaii
Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 2562. CrossRef - Bioengineering bacterial outer membrane vesicles as vaccine platform
Matthias J.H. Gerritzen, Dirk E. Martens, René H. Wijffels, Leo van der Pol, Michiel Stork
Biotechnology Advances.2017; 35(5): 565. CrossRef
- Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy
First
Prev
